The perception that pills are less intense than infusions is a misconception. Patients on oral PARP inhibitors require constant monitoring for side effects like fatigue, nausea, and hematologic toxicities, especially in the first three months.
This is an unusual dosing paradigm outside of pediatrics. Nurses must pay close attention to whether a patient weighs less than 170 lbs or has a platelet count below 150k to determine the correct starting dose, which is crucial for managing toxicity.
Nurses can proactively educate patients that if ocular side effects occur, they will likely manifest around the second cycle, between days 10 and 14. This specific timing helps manage patient anxiety and ensures prompt reporting and intervention.
Unlike cancers where testing is selective, it's a universal standard for ovarian cancer. This impacts not only family members through cascade testing but also directly informs the patient's treatment plan, particularly with PARP inhibitors.
This is a crucial concept for predicting ADC toxicities. ADCs with a topoisomerase payload (like TDXD) cause nausea and myelosuppression, while those with a tubulin inhibitor payload (like MERV) cause neuropathy and ocular issues.
Proactive measures like cascade testing and risk-reducing surgeries are lowering new diagnoses. However, improved treatments mean patients are living longer, leading to a larger population of individuals actively managing the disease.
Achieving remission in ovarian cancer is common, but it's often not sustainable. The strategic use of maintenance therapies, like oral PARP inhibitors, is essential to prolonging the cancer-free period and is a central focus of modern treatment.
While PARP inhibitors show some effect in all patients, clinical data revealed a significant survival advantage only in the HRD-positive subgroup. This has led to an FDA restriction, making biomarker testing a prerequisite for this class of drugs.
High cortisol, a stress hormone, is linked to worse outcomes in ovarian cancer. Relacorilant, by blocking its receptor, appears to overcome chemo resistance by allowing the body's own immune system to help fight the cancer.
Rather than passively waiting for orders, nurses can actively check patient charts for required tests (HRD, Folate Receptor Alpha, HER2, PD-L1) and remind the physician, preventing treatment delays and ensuring access to targeted therapies.
Nurses can better anticipate and educate patients about immunotherapy side effects by understanding their typical timeline. Skin and GI issues often appear within the first month, while thyroid or other endocrine problems may not manifest for two months or more.
GYN oncology nurses are accustomed to GI and hematologic side effects. With mirvetuximab, they must now manage eye-related issues, requiring patient education on prophylactic eye drops and coordination with ophthalmologists for regular exams.